GlassScriptPhysician profile
Richard W Pigg
NPI 1801154901
$12,887.97
in general payments reported to CMS, 2019-2025
45 companies · $1,942 in 2025
The $1,942 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,020 · 2020: $1,437 · 2021: $1,537 · 2022: $1,905 · 2023: $2,129 · 2024: $1,918 · 2025: $1,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,988.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,523.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,481.94 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,031.49 | 2019-2025 | |
| Lilly USA, LLC | $768.78 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $743.47 | 2019-2025 | Jardiance |
| Abbvie INC. | $702.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $563.50 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $538.11 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $452.96 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $424.93 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $391.58 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $384.98 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $297.78 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $261.44 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Novartis Pharmaceuticals Corporation | $228.19 | 2019-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $217.41 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $210.02 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $172.48 | 2023-2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $161.93 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Stryker Corporation | $160.64 | 2025 | Artix Mt |
| Trisalus Life Sciences, INC. | $133.05 | 2024 | Trinav Infusion System |
| Esperion Therapeutics, INC. | $122.85 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $107.89 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $89.96 | 2021-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $84.38 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.75 | 2024-2025 | Caplyta |
| Eisai INC. | $68.46 | 2020-2021 | |
| Exact Sciences Corporation | $57.22 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $54.62 | 2021-2024 | Livalo |
| Biohaven Pharmaceuticals, INC. | $52.82 | 2021 | |
| Pacira Therapeutics, INC. | $50.99 | 2019-2021 | |
| Dexcom, INC. | $47.07 | 2024-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $33.22 | 2022 | |
| Nevro Corp. | $21.56 | 2023 | Senza |
| Cashflow Solutions, LLC | $21.44 | 2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Insulet Corporation | $18.51 | 2025 | Omnipod |
| Sumitomo Pharma America, INC. | $18.05 | 2023 | Gemtesa |
| Daiichi Sankyo INC. | $16.78 | 2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $15.99 | 2024 | Voquezna |
| Gilead Sciences, INC. | $15.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.12 | 2020 | |
| Bioventus LLC | $13.11 | 2020 | |
| Mylan Specialty L.P. | $12.92 | 2022 | |
| Sanofi Pasteur INC. | $12.85 | 2023 | |
| Ibsa Pharma INC. | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Pigg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.